Literature DB >> 8300137

A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells.

Y W Huang1, E S Vitetta.   

Abstract

A monoclonal antibody (UV4) against the human IL-6 receptor (hIL-6R) was generated by immunizing BALB/c mice with both a human myeloma cell line (U266) and a murine cell line (M12.4/R) transfected with the hIL-6R cDNA. Flow cytometric analysis demonstrated that UV 4 stains the hIL-6R+ cell lines U266 and U937, but not the hIL-6R- cell lines Daudi and K562. Competitive inhibition assays demonstrated that preincubation of U266 cells with UV4 inhibited the binding of a phycoerythrin (PE)-IL-6 conjugate to the hIL-6R and also inhibited the proliferative activity of IL-6 on the IL-6-dependent human myeloma cell lines ILKM2 and ILKM3. In contrast, UV4 did not interfere with the proliferation of the hIL-6R- Burkitt's lymphoma cell line, Daudi. Direct sandwich radioimmunoassays further confirmed that the UV4 bound to the same molecule as the goat anti-hIL-6R antibody. These results suggest that both UV4 and human IL-6 bind to the same or adjacent epitopes on the hIL-6R. This monoclonal antibody should facilitate studies of the structure-function relationship of IL-6R and may be useful for the treatment of IL-6-dependent diseases such as multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8300137     DOI: 10.1089/hyb.1993.12.621

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  3 in total

1.  Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.

Authors:  Yabing Cao; Yongsheng Lan; Jianfei Qian; Yuhuan Zheng; Sungyoul Hong; Haiyan Li; Michael Wang; Larry W Kwak; Dongyu Lin; Jing Yang; Qing Yi
Journal:  Br J Haematol       Date:  2011-05-09       Impact factor: 6.998

2.  Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.

Authors:  Jing Yang; Yabing Cao; Sungyongl Hong; Haiyan Li; Jianfei Qian; Larry W Kwak; Qing Yi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

3.  IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells.

Authors:  B E Barton; T F Murphy; P Adem; R A Watson; R J Irwin; H F Huang
Journal:  BMC Cancer       Date:  2001-10-31       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.